After Another Negative Phase 3 Trial Result, Calls for Rethinking Idiopathic Pulmonary Fibrosis | 2024 ATS
An investigational monoclonal antibody to treat idiopathic pulmonary fibrosis failed in a phase 3 trial, according to results presented today at the 2024 American Thoracic Society (ATS) International Conference in San Diego. The negative results for …